UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

6 First and further lines of therapy in clear cell renal cell carcinoma

Critical reviews in oncology/hematology, 2011, Vol.78, p.S5-S5

Rini, B.I

2011

Volltextzugriff (PDF)

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Annals of oncology, 2012-06, Vol.23 (6), p.1549-1555

2012

Volltextzugriff (PDF)

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Annals of oncology, 2020-09, Vol.31, p.S559-S560

2020

Volltextzugriff (PDF)

501 Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial

European journal of cancer (1990), 2015-09, Vol.51, p.S102-S103

2015

Volltextzugriff (PDF)

Erratum to “B.I. Rini, E.J. Small, The potential for prostate cancer immunotherapy” [Crit. Rev. Oncol./Hematol. 46 (2003) S117–S127]

Critical reviews in oncology/hematology, 2012-09, Vol.83 (3), p.452-452

2012

Volltextzugriff (PDF)

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)

European journal of cancer (1990), 2017-02, Vol.72, p.S187-S188

2017

Volltextzugriff (PDF)

359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinib

European journal of cancer (1990), 2014-11, Vol.50, p.116-116

2014

Volltextzugriff (PDF)

Early Salvage Pelvic Radiation Therapy for Lymph Node–Positive Prostate Cancer Following Prostatectomy

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S439-S439

2014

Volltextzugriff (PDF)

2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)

European journal of cancer (1990), 2015-09, Vol.51, p.S519-S520

2015

Volltextzugriff (PDF)

Clinical Outcome of Stereotactic Radiosurgery for Central Nervous System Metastases From Renal Cell Carcinoma

Clinical genitourinary cancer, 2014-04, Vol.12 (2), p.111-116

2014

Volltextzugriff (PDF)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2018-04, Vol.378 (14), p.1277-1290

2018

Volltextzugriff (PDF)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Annals of oncology, 2020-08, Vol.31 (8), p.1030-1039

2020

Volltextzugriff (PDF)

7140 POSTER A Randomized Phase 2 Study of Axitinib Dose Titration in Patients With Advanced Renal Cell Carcinoma (RCC): Preliminary Pharmacokinetic and Ambulatory Blood Pressure (BP) Monitoring Results

European journal of cancer (1990), 2011, Vol.47, p.S517-S517

2011

Volltextzugriff (PDF)

1703P Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study

Annals of oncology, 2024-09, Vol.35, p.S1021-S1021

2024

Volltextzugriff (PDF)

1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

European journal of cancer (1990), 2011, Vol.47, p.S98-S99

2011

Volltextzugriff (PDF)

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

Annals of oncology, 2015-07, Vol.26 (7), p.1300-1304

2015

Volltextzugriff (PDF)

A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

European journal of cancer (1990), 2014-04, Vol.50 (6), p.1084-1089

2014

Volltextzugriff (PDF)

COVID-19 vaccination and breakthrough infections in patients with cancer

Annals of oncology, 2022-03, Vol.33 (3), p.340-346

2022

Volltextzugriff (PDF)

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

Annals of oncology, 2015-07, Vol.26 (7), p.1372-1377

2015

Volltextzugriff (PDF)

745MO Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study

Annals of oncology, 2023-10, Vol.34, p.S510-S510

2023

Volltextzugriff (PDF)

717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)

Annals of oncology, 2021-09, Vol.32, p.S722-S723

2021

Volltextzugriff (PDF)

1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study

Annals of oncology, 2024-09, Vol.35, p.S1024-S1025

2024

Volltextzugriff (PDF)

1697P Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis

Annals of oncology, 2024-09, Vol.35, p.S1017-S1017

2024

Volltextzugriff (PDF)

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Annals of oncology, 2014-01, Vol.25 (1), p.149-154

2014

Volltextzugriff (PDF)

1910P Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)

Annals of oncology, 2023-10, Vol.34, p.S1028-S1028

2023

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(82)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Humans
(19)
Life Sciences & Biomedicine
(19)
Oncology
(18)
Carcinoma, Renal Cell - Drug Therapy
(14)
Hematology, Oncology And Palliative Medicine
(13)
Kidney Neoplasms - Drug Therapy
(13)
Renal Cell Carcinoma
(13)
Male
(11)
Kidney Neoplasms - Pathology
(10)
Middle Aged
(10)
Female
(9)
Aged
(8)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Pharmacology. Drug Treatments
(8)
Adult
(7)
Antineoplastic Agents
(7)
Carcinoma, Renal Cell - Secondary
(7)
Sunitinib
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

6 First and further lines of therapy in clear cell renal cell carcinoma

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

501 Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial

Erratum to “B.I. Rini, E.J. Small, The potential for prostate cancer immunotherapy” [Crit. Rev. Oncol./Hematol. 46 (2003) S117–S127]

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)

359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinib

Early Salvage Pelvic Radiation Therapy for Lymph Node–Positive Prostate Cancer Following Prostatectomy

2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)

Clinical Outcome of Stereotactic Radiosurgery for Central Nervous System Metastases From Renal Cell Carcinoma

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

7140 POSTER A Randomized Phase 2 Study of Axitinib Dose Titration in Patients With Advanced Renal Cell Carcinoma (RCC): Preliminary Pharmacokinetic and Ambulatory Blood Pressure (BP) Monitoring Results

1703P Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study

1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

COVID-19 vaccination and breakthrough infections in patients with cancer

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

745MO Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study

717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)

1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study

1697P Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

1910P Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)

Suchergebnisse filtern